Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from October 28, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on January 26, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$52.58 Published $61.52 Target $63.98 Window close $64.16 Peak
$52.00 – $53.30Entry zone — fair-value band
$52.58Published — price the day we called it
$61.52Target — the price the thesis aimed for
$64.16Peak — highest point inside the window, not a realized return
$63.98Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 80 days.

Peak price
$64.16
peak on January 23, 2026 — not a realized return
Peak gain
+22%
peak, from the publication price
Window close
$63.98
end-of-window price, context only
Days to target
80
Window
October 28, 2025 – January 26, 2026

The thesis — published October 28, 2025

Predicted growth
+17%
over the measurement window
Target price
$61.52
the price the thesis aimed for
Entry zone
$52.00 – $53.30
the fair-value band we waited for
Price at publication
$52.58
published October 28, 2025
Confidence
67%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

NVO looks like a strong company whose stock has fallen more than usual, while investor mood stays positive. Upcoming Wegovy liver-disease study results at a major medical meeting could refresh interest after a small analyst target cut. Because Novo Nordisk leads in obesity medicines and the market backdrop is decent, a bounce seems reasonable. Main watch-outs: rivals, tight supply, and pressure on prices.

Primary drivers

  • Stock looks unusually beaten down, creating a potential near-term recovery setup.
  • Near-term Wegovy liver study results may spark fresh interest and media attention.
  • Company is the clear leader in modern obesity drugs, a fast-growing treatment area.
  • Investor mood remains upbeat despite a small analyst target cut recently.

How it played out

NVO: target reached in 80 days

Lyra published NVO at 52.58 on 2025-10-28 with an expected gain of 17%. The thesis pointed to an unusually beaten-down stock, possible interest from upcoming Wegovy liver study results, Novo Nordisk's lead in modern obesity drugs, and investor mood that stayed upbeat despite a small analyst target cut. It also named rivals, tight supply, and pricing pressure as watch-outs.

Inside the window, the stock reached the 61.52 target in 80 days. It peaked at 64.16 on 2026-01-23, a 22% gain. It ended at 63.98 on 2026-01-26. The published thesis played out.

What happened during the window

On 2025-11-05, Novo Nordisk reported third-quarter results and reduced its full-year outlook. On 2026-01-05, the company launched an oral Wegovy weight-loss pill in the U.S.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals